This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
AEterna Zentaris, Inc.
Drug Names(s): EP-1572, ARD-07, Growth Hormone Secretagogue (GHS), macimorelin
BioMedTracker has two separate profiles for the therapeutic and diagnostic development of AEZS-130. Please also see AEZS-130 (Diagnostic).
AEZS-130 is an orally administered non-peptidyl growth hormone secretagogue, which stimulates the release of growth hormone. It is thought to work without the involvement of Growth Hormone Releasing Hormone (GH-RH) or somatostatin. Its target is the ghrelin receptor, formally known as the growth hormone secretagogue receptor.
AEterna Zentaris and Ardana
In 2002, AEterna Zentaris granted Ardana an exclusive worldwide license to develop and market the growth hormone secretagogue EP-1572. Ardana is funding the activities necessary to obtain regulatory and marketing approvals. Furthermore, the agreement provides milestone payments, as well as royalties on future worldwide net sales of EP-1572 among other elements to AEterna Zentaris.
In November 2008, AEterna announced that it has recovered worldwide rights from Ardana plc for AEZS-130.
AEZS-130 (Therapeutic) News
Pink Sheet FDA Performance Tracker: CDER Approvals
Additional information available to subscribers only: